Abstract 244: The Potential Population Health Impact Of Treating US Adults With Icosapent Ethyl.
Background: To estimate the population health impact of treating all US adults eligible for the Reduction of Cardiovascular Events with
Read moreBackground: To estimate the population health impact of treating all US adults eligible for the Reduction of Cardiovascular Events with
Read moreAims: Modeling estimates indicate that heart failure (HF) prevalence may be lowest in low-income (LICs). Conversely, HF has been shown
Read moreBackground: The need to handle a growing number of advanced heart failure (HF) patients has fueled growth in heart transplantation
Read moreBackground: Angiotensin receptor neprilysin inhibitors (ARNI) can significantly reduce mortality and hospitalization for patients with heart failure (HF). However, relatively
Read moreBackground: The Reduction of Cardiovascular Events with Icosapent Ethyl (IE)-Intervention Trial (REDUCE-IT) demonstrated the efficacy of IE among patients with
Read moreHeart failure is a leading diagnosis for hospitalization with a high risk of readmission. Despite robust data and recommendations by
Read moreIntroduction: Congenital heart defects (CHD) are the most common birth defects and are estimated to affect almost 1% of births
Read moreGlobal longitudinal strain (GLS) analysis via speckle tracking echocardiography is a relatively new and promising imaging technology for the assessment
Read moreBackground: Impact of social isolation associated with the COVID-19 pandemic on the severity and frequency of cardiac symptoms has not
Read moreBackground: Cholesterol treatment is central to cardiovascular risk reduction, but disparities in management may exist. Our hypothesis is that demographic
Read more